bBHC developed new type of novel pluripotent stem cells which is called KHCs. This novel cell type was induced from umbilical cord mesenchymal stem cells (UC MSCs) by treatment with natural compounds without genetic manipulation and demonstrated the ability to differentiate into endoderm, mesoderm, and ectoderm. The conversion efficiency from umbilical cord mesenchymal stem cells was over 90%. It exhibited increased expression of anti-aging and tumor-suppressor genes, transcription factors essential for blastocyst formation, and cytotoxic T-cell markers, while significantly inhibiting cancer cell survival and invasion. The novel cells identified in this study exhibit minimal immunogenicity and extremely low tumorigenicity, making them suitable for allogeneic applications. Additionally, they have the potential to play a significant role in the prevention and treatment of cancer and aging-related diseases.